Wall Street brokerages predict that Alpine Immune Sciences Inc (NASDAQ:ALPN) will post earnings of ($0.60) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Alpine Immune Sciences’ earnings, with estimates ranging from ($0.72) to ($0.51). Alpine Immune Sciences reported earnings of ($0.33) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 81.8%. The firm is expected to issue its next earnings results on Wednesday, March 27th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.12) per share for the current fiscal year, with EPS estimates ranging from ($2.32) to ($1.98). For the next fiscal year, analysts expect that the firm will post earnings of ($2.46) per share, with EPS estimates ranging from ($2.85) to ($1.94). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 26.00%.
Large investors have recently modified their holdings of the stock. DRW Securities LLC raised its holdings in shares of Alpine Immune Sciences by 138.7% during the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 14,143 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after acquiring an additional 21,124 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 18,052 shares during the period. Institutional investors own 56.87% of the company’s stock.
Shares of ALPN traded down $0.01 during mid-day trading on Monday, hitting $4.80. 9,821 shares of the company traded hands, compared to its average volume of 15,467. Alpine Immune Sciences has a 1-year low of $4.61 and a 1-year high of $11.75. The company has a quick ratio of 20.99, a current ratio of 20.99 and a debt-to-equity ratio of 0.05. The company has a market cap of $66.77 million, a P/E ratio of -4.00 and a beta of 0.94.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Article: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.